Abstract: The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.
Type:
Grant
Filed:
February 26, 2005
Date of Patent:
January 10, 2012
Assignee:
Metaproteomics, LLC
Inventors:
John G. Babish, Matthew L. Tripp, Jeffrey S. Bland
Abstract: The object of the invention relates to a development of a new musk-feeling fragrance material which is a highly scenting musk-feeling fragrance, and is to provide a fragrance composition which, when added to fragrances or cosmetics, can improve the fixative property and express a high performance and excellent musky aromatic quality. A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 75:25 to 80:20 (weight ratio) in terms of weight ratio.
Abstract: A pharmaceutical composition for hepatitis treatment, which comprises lucidone as an active ingredient; and a pharmaceutical acceptable carrier. As lucidone is a natural cyclopentenedione, the pharmaceutical composition of present invention has lesser side effects. The present invention is also related to the application of the pharmaceutical composition.
Abstract: Disclosed are: a coenzyme Q10 composition for oral ingestion which improves the bioabsorbability of coenzyme Q10 and enables efficient ingestion of coenzyme Q10 and which is highly safe, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. Combining coenzyme Q10 and a seed processed product has made it possible to provide a coenzyme Q10-containing composition for oral ingestion excellent in bioabsorbability, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion.
Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.
Abstract: A flavor and fragrance composition with a cooling sensation effect comprising 1-(2-hydroxy-4-methylcyclohexyl)ethanone represented by the formula (1). The flavor and fragrance composition is added to a beverage or food product, a fragrance or cosmetic product, a daily utensil product, an oral composition, or a pharmaceutical product in the range of 0.0001 to 20% by weight to the total weight of the flavor and fragrance composition added.
Abstract: A product and method for controlling mouth odor and bad breath using an oral care product containing an odor neutralizer. The product for use in oral care or for use in the mouth to control mouth odors includes an odor neutralizer compound. In a preferred method of manufacture, the O.M. Complex oral compound is mixed into a concentrated flavor material. The concentrated flavor material is then added in small percentages to the product during manufacture so that the resulting product includes the odor neutralizer compound. The product may be used in the ordinary manner by a user and during use the O.M. Complex oral compound serves to capture and neutralize odor causing compounds.
Abstract: To provide a drug, quasi-drug, food or drink that can act as a gastric acid secretion suppressant or a potassium channel inhibitor by including a composition that can be safely used and can be inexpensively produced. Each of these products contains one or more cooling sensation compositions that are compounds providing cooling sensation in an amount sufficient for exhibiting the efficacy thereof in a living body to which the product is administered.
Type:
Application
Filed:
January 26, 2010
Publication date:
November 17, 2011
Inventors:
Yuichi Suzuki, Kenya Ishida, Mitsuhiko Fujiwhara
Abstract: Synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases; chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease and a targeted nano delivery of bioactive compounds and/or bioactive molecules are described. Furthermore, microelectro-mechanical system (Mems) based passive and active (based on feedback diagnostics data) delivery systems and methods of bioactive compounds and/or bioactive molecules are also described.
Abstract: Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form.
Type:
Application
Filed:
December 10, 2009
Publication date:
November 10, 2011
Applicant:
Metaproteomics, LLC
Inventors:
Brian J. Carroll, Clinton J. Dahlberg, James S. Traube
Abstract: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation.
Abstract: The formulations of the present disclosure alter the perception of pain, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as fibromyalgia. The present disclosure encompasses formulations for the relief of symptoms associated with neuropathy pain, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, and folic acid. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and cholinebitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating neuropathy related pain in subject animal or human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, and water.
Abstract: The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
Type:
Grant
Filed:
February 22, 2007
Date of Patent:
October 25, 2011
Assignee:
Georgetown University
Inventors:
Alan P. Kozikowski, Alan I. Faden, Gian Luca Araldi
Abstract: The present invention relates to mixtures comprising a) a compound of the formula I in which X, m, Q and a are as defined in the description and b) one or more ethylene modulators (II) selected from the group consisting of: inhibitors of ethylene biosynthesis which inhibit the conversion of S-adenosyl-L-methionine into 1-aminocyclopropane-1-carboxylic acid (ACC), inhibitors of ethylene biosynthesis which block the conversion of ACC into ethylene, or inhibitors of ethylene action, and also to compositions comprising them and to their use for controlling harmful fungi.
Type:
Grant
Filed:
November 5, 2004
Date of Patent:
October 25, 2011
Assignee:
BASF SE
Inventors:
Wilhelm Rademacher, John S. Harden, Dan E. Westberg, Joseph E. Zawierucha, Thomas J. Holt, Hendrik Ypema, Ted R. Bardinelli, Albert C. Everson, Edson Begliomini
Abstract: Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form.
Type:
Application
Filed:
December 10, 2009
Publication date:
October 20, 2011
Applicant:
Metaproteomics, LLC
Inventors:
Brian J. Carroll, Clinton J. Dahlberg, James S. Traub
Abstract: The presently claimed and disclosed invention(s) provides a therapeutically effective composition and method of inhibiting nerve cell transmission. In a preferred embodiment of the presently claimed and disclosed invention(s), the treatment of neuropathic pain utilizing terpene compounds isolated from plant essential oils or manufactured synthetically is detailed. These compounds, such as geraniol and citronellol, as well as chemical analogs thereof, used in combination or individually, can be used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form.
Abstract: This invention relates to a group of compounds for repelling blood-feeding ectoparasitic arthropods, and a method of deterring their landing and feeding on animals including humans, by applying in one or more formulations compounds that incorporate one or more sulfide and one or more hydroxyl groups to the skin, clothing or environment of animals, including humans. A method of repelling and deterring landing and feeding by blood-feeding arthropods on an animal by applying in effective amount one or more compounds that incorporate alkyl sulfide and alcohol moieties, or alkyl sulfide and amide moieties, or alkyl sulfide and amide moieties to the skin, clothing or environment of an animal.
Type:
Application
Filed:
September 25, 2009
Publication date:
October 13, 2011
Inventors:
Regine M Gries, Grigori Khaskin, Gerhard G. Gries
Abstract: Provided are compositions and methods for clear and stable beverages that contain additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.
Abstract: The present invention provides novel 2,6-diisopropyl phenol2,6-diisopropyl phenol analogs and sterile, stable pharmaceutical compositions of 2,6-diisopropyl phenol 2,6-diisopropyl phenol and analogs thereof useful as an antioxidant in the treatment of ischemic injury including stroke and other cerebral injury. 2,6-diisopropyl phenol or its analogs are administered in a dosage effective to produce blood levels and brain levels of the drug that can prevent free radical damage associated with ischemic injury.
Type:
Grant
Filed:
February 17, 2006
Date of Patent:
September 27, 2011
Assignee:
Abraxis BioScience, LLC
Inventors:
Neil P. Desai, Chunlin Tao, Cheng Zhi Yu, Vuong Trieu, Patrick Soon-Shiong
Abstract: Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C.
Type:
Application
Filed:
March 11, 2011
Publication date:
September 22, 2011
Inventors:
Niven Rajin Narain, John Patrick McCook
Abstract: A process for the production of a soluble composition comprising a water-insoluble active which comprises either the steps of: a) providing a liquid mixture comprising: i) a dissolved water-insoluble active, ii) a dissolved water-soluble carrier, iii) a solvent for each of the active and the carrier, and b) spray-granulating the mixture to remove the, or each, solvent and obtain a substantially solvent-free nano-dispersion of the water-insoluble active in the carrier said water-insoluble active being in nano-particles having a size range of 999-20 nm; or, the steps of: a) providing a substantially solvent-free powder comprising a water-insoluble active dispersed in a water soluble carrier, said water-insoluble active being in nano-particles having a size range of 999-20 nm, and, b) spray-granulating the powder to obtain larger and denser particles. The invention also relates to solvent-free, granular products with a particle size in the range 20 microns to 10 mm and a bulk-density of greater than 0.
Type:
Application
Filed:
July 24, 2009
Publication date:
September 8, 2011
Inventors:
Doris Angus, Alison Jayne Foster, David Duncalf, Steven Paul Rannard, Dong Wang
Abstract: A therapeutic composition having at least one botanical active ingredient, carvone, derived from plants such as mint Mentha sp., caraway Carum carvi or dill Anethum graveolens. Carvone is capable of anesthetizing teleost, elasmobranch, and agnathan fishes as well as amphibians by contact with skin and/or gills. Carvone has two natural enantiomers; both have anesthetic properties on these fishes and amphibians. Carvone in combinations with other sodium channel blockers such as methyl salicylate have a synergistic effect and are more efficient at anesthetizing teleosts, elasmobranchs and agnathan fishes than carvone alone. This invention has value because it offers an opportunity to forumulate fish anesthetizing drugs with a compound that is also documented to be safe for human consumption.
Abstract: The present invention relates to a chemical combination and method for increasing delivery of Coenzyme Q10. The chemical combination comprises Coenzyme Q10 mixed with at least one chemical. The at least one chemical includes cyclic monoterpene containing essential oil(s) that permit unprecedented levels of Coenzyme Q10 to be made available for delivery and absorption, increasing bioavailability, as well as overcoming the previous limits.
Abstract: The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention further provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject.
Abstract: The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.
Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and a quinone, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.
Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR).
Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the retinoid compound is concentration dependent, with the amount of retinoid photostabilization increasing with the concentration of the alkoxycrylene compound.
Type:
Application
Filed:
February 22, 2011
Publication date:
June 16, 2011
Applicant:
HALLSTAR INNOVATIONS CORP.
Inventors:
Craig A. Bonda, Anna Pavlovic, Jean Zhang
Abstract: Compositions and methods to promote or maintain weight loss utilizing tetrahydro-isoalpha acid compounds are disclosed. Methods to increase synthesis of GLP-1 are disclosed.
Type:
Application
Filed:
August 13, 2010
Publication date:
June 9, 2011
Applicant:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, Gary Darland, Veera Konda
Abstract: This invention provides a pharmaceutical and functional food which are made of a safe food ingredient or nutrient which has been used for a long period of time, and which have tranquilizing effect such as anti-anxiety effect, anti-depression effect, and anti-stress effect. The tranquilizer of the invention contains vitamin K as an active ingredient. Vitamin K is preferably menaquinone-4 and/or menaquinone-7. This invention also provides a supplement, health food or functional food for tranquilizing purpose that contains vitamin K as an active ingredient.
Abstract: The present invention provides a stabilization method of reduced coenzyme Q10 useful as food, food with nutrient function claims, food for specified health uses, nutritional supplement, nutritional supplement, animal drugs, drinks, feeds, cosmetics, pharmaceutical products, therapeutic drugs, prophylactic drugs and the like, as well as a stabilized composition. Furthermore, it provides a convenient production method of reduced coenzyme Q10 using oxidized coenzyme Q10 as a starting material. In the present invention, oxidation of reduced coenzyme Q10 can be suppressed, and reduced coenzyme Q10 can be stably maintained by the co-presence of a licorice hydrophobic extract and reduced coenzyme Q10. In addition, reduced coenzyme Q10 can be produced by the co-presence of oxidized coenzyme Q10 and a licorice hydrophobic extract.
Abstract: The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1—R6, Ra—Rc, Q, Y1, Y2 and n are as defined herein.
Type:
Grant
Filed:
March 26, 2004
Date of Patent:
May 17, 2011
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Samuel J. Danishefsky, Christoph Gaul, Jon T. Njardarson
Abstract: Pre-treatment using a xanthin carotenoid (preferably 3R,3?R-zeaxanthin) can improve the benefits and efficacy of photodynamic therapy (PDT), which uses a light-activated drug (such as verteporfin) in patients who suffer from unwanted retinal blood vessel growth, including the “wet” (exudative) form of macular degeneration. Before a PDT treatment, patients are given a regimen of orally-ingested zeaxanthin for a period of at least 1 and preferably at least 2 to 3 weeks, at dosages of at least 3 and preferably at least 10 milligrams per day. Since zeaxanthin imparts a yellowish color to the macula, a preferred dosage should increase a patient's macular pigment density before the PDT treatment is performed.
Abstract: The present invention relates to 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone) for treating and/or preventing respiratory illness associated with certain forms of muscular dystrophy.
Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
Type:
Grant
Filed:
November 5, 2007
Date of Patent:
April 19, 2011
Assignee:
Board of Regents of the University of Texas System
Inventors:
Robert A. Kirken, Barry D. Kahan, Stanislaw M. Stepkowski, Waldemar Priebe, Izabela Fokt, Szymon Kosinski
Abstract: The present invention relates to compositions containing plant gums and one or more fat-soluble active ingredients, wherein the composition comprises less than 40 weight-% oil, based on the total composition in dry matter. These compositions can be used for the enrichment, fortification and/or coloration of food beverages, animal feed, cosmetics or pharmaceutical compositions. The present invention also refers to the preparation of such compositions. The present invention furthermore refers to a process for the manufacture of a beverage by mixing the compositions with ingredients of beverages. The present invention also refers to beverages obtainable by this process.
Type:
Application
Filed:
June 3, 2009
Publication date:
April 7, 2011
Inventors:
Andrea Hitzfeld, Bruno H. Leuenberger, Olivia Vidoni
Abstract: The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.
Type:
Grant
Filed:
February 27, 2004
Date of Patent:
March 29, 2011
Assignee:
Metaproteomics, LLC
Inventors:
John G. Babish, Matthew L. Tripp, Jeffrey S. Bland
Abstract: Articles having metallic finishes including antimicrobial agents dispersed throughout the finish and methods of electroplating said metallic finishes on a material. The metallic finishes include highly-decorative electroplated finishes for bathroom and kitchen hardware, door hardware, and other highly lustrous products where antimicrobial protection is preferred.
Type:
Application
Filed:
March 25, 2009
Publication date:
March 17, 2011
Applicants:
PAVCO INC., MICROBAN INTERNATIONAL LTD.
Inventors:
Leonard L. Diaddario, Matthew W. Stauffer
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of colorectal cancer cells and be used as a pharmaceutical composition to inhibit the colorectal tumor growth.
Type:
Application
Filed:
September 7, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of lymphoma cells and be used as a pharmaceutical composition to inhibit the lymphoma tumor growth.
Type:
Application
Filed:
August 30, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of bladder cancer cells and be used as a pharmaceutical composition to inhibit the bladder tumor growth.
Type:
Application
Filed:
September 7, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of ovarian cancer cells and be used as a pharmaceutical composition to inhibit the ovarian tumor growth.
Type:
Application
Filed:
September 3, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3 -dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of skin cancer cells and be used as a pharmaceutical composition to inhibit the skin tumor growth.
Type:
Application
Filed:
September 3, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of oral cavity cancer cells and be used as a pharmaceutical composition to inhibit the oral cavity tumor growth.
Type:
Application
Filed:
September 7, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of gastric cancer cells and be used as a pharmaceutical composition to inhibit the gastric tumor growth.
Type:
Application
Filed:
September 3, 2010
Publication date:
March 10, 2011
Applicant:
GOLDEN BIOTECHNOLOGY CORPORATION
Inventors:
Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
Abstract: The present invention relates to an agent for suppressing STAT3 phosphorylation and for suppressing Notch1 expression comprising as an active ingredient a compound represented by the following formula (1): wherein R1, R2 and R3 each independently represents a hydrogen atom or a methyl group; and X represents a linear or branched alkyl, alkylene or alkenylene group having 10 to 28 carbon atoms.
Type:
Grant
Filed:
October 13, 2005
Date of Patent:
February 15, 2011
Assignee:
Meiji Dairies Corporation
Inventors:
Bang Luu, Ellane Mohier, Masashi Yamada, Hiroto Suzuki
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandin selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops.
Type:
Application
Filed:
April 7, 2010
Publication date:
January 27, 2011
Applicant:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.